Anixa Biosciences Inc 10-Q

Item 5. Other Information. None. Item 6. Exhibits. 10.1 Amendment to License Agreement between Certainty Therapeutics, Inc. and The Wistar Institute of Anatomy and Biology. (Certain information has been redacted in the marked portions of the exhibit.) 10.2 Joint Development and Option Agreement, dated January 26, 2021, between the Company and The Cleveland Clinic Foundation. (Certain information has been redacted in the marked portions of the exhibit.) 31.1 Certification of Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated March 11, 2021. 31.2 Certification of Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, dated March 11, 2021. 32.1 Statement of Chief Executive Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated March 11, 2021. 32.2 Statement of Chief Financial Officer, pursuant to Section 1350 of Title 18 of the United States Code, dated March 11, 2021. 26 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ANIXA BIOSCIENCES, INC. By: /s/ Dr. Amit Kumar Dr. Amit Kumar Chairman, President and Chief Executive Officer March 11, 2021 (Principal Executive Officer) By: /s/ Michael J. Catelani Michael J. Catelani Chief Operating Officer and Chief Financial Officer March 11, 2021 (Principal Financial and Accounting Officer) 27